Skip to main content
Oxford Research Peptides
COMPARISON

Semaglutide vs Retatrutide

A structured, evidence-based comparison of a selective GLP-1 receptor agonist and an investigational GLP-1/GIP/GCG triple agonist — for researchers working with either compound as a reference standard.

QUICK ANSWER
TL;DR

Quick answer

Semaglutide is a long-acting selective GLP-1 receptor agonist with a large human evidence base. Retatrutide is an investigational triple agonist (GLP-1R + GIPR + GCGR) with preclinical and early-clinical evidence. The two compounds differ primarily in receptor coverage and evidence maturity, not in the core albumin-binding half-life-extension strategy they share.
EXTENDED ANSWER
AI-ready

Extended answer

How do Semaglutide and Retatrutide compare?

Semaglutide is a synthetic long-acting GLP-1 receptor agonist derived from native GLP-1(7-37), engineered with an Aib8 substitution and a C18 fatty-di-acid at Lys26 that supports albumin binding. It is a selective GLP-1 mono-agonist with a plasma half-life of approximately one week and an extensive human evidence base spanning glycaemic, cardiovascular, renal and hepatic endpoints. Retatrutide (LY3437943) is an investigational triple agonist engineered to activate the GLP-1, GIP and glucagon receptors from a single molecule. It carries a fatty-acid modification that supports once-weekly kinetics but its evidence base is currently preclinical and early clinical — phase 2 obesity data have been published, phase 3 outcome data have not. The pharmacological distinction is receptor coverage; the clinical distinction is evidence maturity. Oxford Research Peptides supplies both compounds as lyophilised reference standards for in-vitro laboratory research only.
KEY FACTS

Key facts

Semaglutide class
Selective GLP-1R agonist
Retatrutide class
Triple agonist (GLP-1R + GIPR + GCGR)
Semaglutide half-life
≈ 1 week
Retatrutide half-life
≈ 6 days (reported phase 1)
Semaglutide evidence tier
Landmark RCTs
Retatrutide evidence tier
Phase 2 / preclinical

Scientific overview

Both Semaglutide and Retatrutide are engineered peptide agonists in the incretin-mimetic family. Semaglutide is a well-characterised selective GLP-1 receptor agonist described in the peer-reviewed literature since 2015.[1] Retatrutide (LY3437943) is an investigational triple agonist described by Coskun and colleagues in 2022 and evaluated in an obesity phase 2 trial reported in 2023.[3][4]

Mechanism comparison

Semaglutide activates GLP-1R alone. Downstream signalling engages Gαs → adenylyl cyclase → cAMP with PKA and EPAC2 effectors, producing glucose-dependent insulinotropic and glucagonostatic effects and slowing gastric emptying. Retatrutide additionally engages GIPR and GCGR from the same molecule, adding an insulinotropic GIP arm and a hepatic glucagon arm that contributes to energy expenditure in preclinical models.[3]

Receptor targets and mechanism
FeatureSemaglutideRetatrutide
Compound classSelective GLP-1R agonistTriple agonist (GLP-1R + GIPR + GCGR)
Primary receptorGLP-1R (class B GPCR)GLP-1R + GIPR + GCGR (class B GPCRs)
G-protein couplingGαs → cAMP → PKA / EPAC2Gαs (all three receptors) → cAMP
Insulinotropic effectYes (GLP-1R, glucose-dependent)Yes (GLP-1R + GIPR, glucose-dependent)
Glucagonostatic effectYes (GLP-1R, glucose-dependent)Partial (GLP-1R offset by GCGR arm)
Hepatic energy expenditure armNo directYes (via GCGR)

Receptor selectivity comparison

Semaglutide is selective at GLP-1R and does not activate GIPR or GCGR at pharmacologically meaningful concentrations. Retatrutide is engineered as a balanced multi-receptor ligand; reported in-vitro potencies at the three receptors are of the same order of magnitude, though relative activity is compound- and assay-dependent.[3]

Pharmacokinetic comparison

Reported pharmacokinetics
ParameterSemaglutideRetatrutide
Plasma half-life (human, SC)≈ 1 week≈ 6 days (reported)
Half-life extension strategyAib8 + C18 di-acid acylation + γGlu-2xOEG spacerFatty-acid acylation supporting albumin binding
Route (approved / investigational)Once-weekly SC (Ozempic/Wegovy); once-daily oral with SNAC (Rybelsus)Once-weekly SC (investigational)
Albumin binding> 99%High (fatty-acid-mediated)
ClearanceProteolysis; renal + faecal excretion of metabolitesProteolysis (early-phase data)

Research applications comparison

Research applications and evidence maturity
Research areaSemaglutideRetatrutide
Type 2 diabetesLandmark RCTs (SUSTAIN-6)Phase 2 signal
Obesity / weight changeLandmark RCTs (STEP-1)Phase 2 signal (Jastreboff 2023)
Cardiovascular outcomesSUSTAIN-6, SELECTNot established
Renal outcomesFLOWNot established
Hepatic (MASH)Imaging and biopsy studiesPreclinical signals
CNS / neuroinflammationPreclinical + early clinicalPreclinical

Human evidence comparison

Semaglutide's human evidence base is substantial and includes cardiovascular outcomes in type 2 diabetes (SUSTAIN-6),[6] weight change in overweight/obesity (STEP-1),[5] and multiple additional endpoints across the SUSTAIN, STEP, PIONEER, SELECT and FLOW programmes. Retatrutide's human evidence is currently a single published phase 2 obesity trial and associated early-phase data.[4]

Preclinical evidence comparison

Both compounds have substantial published preclinical pharmacology. Semaglutide's preclinical characterisation established GLP-1R selectivity and central neural circuit mapping.[1] Retatrutide's preclinical characterisation established balanced tri-receptor activity in rodent and non-human primate models.[3]

Advantages and limitations

  • Semaglutide — advantages: extensive human evidence, well-characterised receptor pharmacology, oral and subcutaneous formulations, established assay methodology.
  • Semaglutide — limitations: mono-agonism may miss additive effects available with multi-receptor ligands; assay potency is highly sensitive to albumin content.
  • Retatrutide — advantages: broader receptor coverage in one molecule, promising early efficacy signals in phase 2.
  • Retatrutide — limitations: limited human evidence base; long-term safety and cardiovascular / renal outcome data not yet published; investigational status.

Research context

Comparative in-vitro work involving both compounds must control rigorously for buffer albumin content and plasticware surface area — the two ligands' apparent EC50 values shift substantially with these variables.

Research-use framing

This comparison summarises published pharmacology. Oxford Research Peptides supplies both Semaglutide and Retatrutide as lyophilised reference standards for in-vitro laboratory research only. Nothing here constitutes medical advice.

Related reading: Semaglutide monograph, Retatrutide monograph, Triple agonists explained, GLP-1 receptor explained, SUSTAIN-6 and SELECT.

References10

  1. 1.

    Lau J, Bloch P, Schäffer L, et al.. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide.. Journal of Medicinal Chemistry. 2015;58(18):7370-7380.

    DOI: 10.1021/acs.jmedchem.5b00726PMID: 26308095
  2. 2.

    Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide.. Frontiers in Endocrinology. 2019;10:155.

    DOI: 10.3389/fendo.2019.00155PMID: 31031702
  3. 3.

    Coskun T, Urva S, Roell WC, et al.. LY3437943, a novel triple glucagon, GIP and GLP-1 receptor agonist for glycemic control and weight loss.. Cell Metabolism. 2022;34(9):1234-1247.e9.

    DOI: 10.1016/j.cmet.2022.07.013PMID: 35914543
  4. 4.

    Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial.. New England Journal of Medicine. 2023;389(6):514-526.

    DOI: 10.1056/NEJMoa2301972PMID: 37366315
  5. 5.

    Wilding JPH, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity (STEP 1).. New England Journal of Medicine. 2021;384(11):989-1002.

    DOI: 10.1056/NEJMoa2032183PMID: 33567185
  6. 6.

    Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6).. New England Journal of Medicine. 2016;375(19):1834-1844.

    DOI: 10.1056/NEJMoa1607141PMID: 27633186
  7. 7.

    Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2).. New England Journal of Medicine. 2021;385(6):503-515.

    DOI: 10.1056/NEJMoa2107519PMID: 34170647
  8. 8.

    Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1).. New England Journal of Medicine. 2022;387(3):205-216.

    DOI: 10.1056/NEJMoa2206038PMID: 35658024
  9. 9.

    Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER).. New England Journal of Medicine. 2016;375(4):311-322.

    DOI: 10.1056/NEJMoa1603827PMID: 27295427
  10. 10.

    Pratley R, Amod A, Hoff ST, et al.. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4).. Lancet. 2018;394(10192):39-50.

    DOI: 10.1016/S0140-6736(19)31271-1PMID: 31186120
EVIDENCE SUMMARY
Evidence

Evidence summary

Strong evidence
Research confidenceHigh confidence
Semaglutide pharmacology and clinical evidence are supported by a large peer-reviewed literature. Retatrutide pharmacology is well characterised preclinically with early-phase clinical data. Comparative claims are consistent with published sources.
RESEARCH LIMITATIONS

Research limitations

  • No head-to-head randomised trial of Semaglutide vs Retatrutide has been published.
  • Retatrutide evidence is limited to preclinical and early-phase clinical data; long-term outcomes are not established.
  • In-vitro potency comparisons of acylated GLP-1 peptides are highly sensitive to assay conditions.
  • Approved-therapeutic evidence for Semaglutide does not describe or endorse research-use handling of reference-standard material.
RELATED GUIDES
COMPOUND REFERENCE
EDITORIAL NOTICE

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
VERSION HISTORY
Editorial Team
Oxford Research Peptides Editorial Team
In-house editorial staff
Oxford Research Peptides
Scientific Reviewer
Scientific Review Panel
Independent scientific review
Oxford Research Peptides

Publication information

Published
2026-10-15
Updated
2026-10-15
Reviewed
2026-10-15
Version
1.0

Revision history

  1. v1.02026-10-15· Editorial Team

    Authority Sprint 2D — initial publication of GLP-1 comparison guides.

Editorial standards

Content is reviewed against our editorial process for scientific accuracy, sourcing, and clarity. Read our editorial standards.

Conflict of interest

Oxford Research Peptides supplies research-grade reference peptides commercially. Editorial pages are drafted and reviewed to describe published scientific literature accurately and do not recommend, promote or endorse any specific commercial product. Product mentions on educational pages are strictly for cross-referencing catalogue entries.

Next scheduled review: 2028-04-15. Our research methodology describes how the review is conducted.

Research use only

All materials referenced are supplied strictly for in-vitro laboratory research. Not for human or animal consumption, diagnosis, or therapeutic use.
Published: 2026-10-15Updated: 2026-10-15